Being a student at UCL is about so much more than just acquiring knowledge. Studying here gives you the opportunity to realise your potential as an individual, and the skills and tools to thrive.
Find out more about what makes UCL research world-leading, how to access UCL expertise, and teams in the Office of the Vice-Provost (Research, Innovation and Global Engagement).
Discover the many ways you can connect with UCL, and how we work with industry, government and not-for-profit organisations to tackle tough challenges.
Founded in 1826 in the heart of London, UCL is London's leading multidisciplinary university, with more than 16,000 staff and 50,000 students from 150 different countries.
We have set up a national programme of immunotherapy clinical trials for patients with glioblastoma. We are currently actively developing new clinical trials.
Selected completed trials
IPI-GLIO A Phase II, Open Label, Randomised Study of Ipilimumab with Temozolomide versus Temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma (IPI-GLIO; ISRCTN84434175). Chief Investigator.
REGAL A phase III, randomised, multi-centre study in subjects with recurrent glioblastoma multiforme to compare the efficacy of cediranib monotherapy and the combination of cediranib with lomustine to the efficacy of lomustine alone.
DORIC A phase II, randomised, multicentre study in subjects with recurrent glioblastoma to compare the efficacy of cediranib plus placebo and the combination of cediranib and gefitinib (Iressa). Chief Investigator and Principal Investigator.
IMA950 A Cancer Research UK Phase I trial of IMA950 (a novel multi-peptide vaccine) plus GM-CSF in patients with newly diagnosed glioblastoma (NCT01222221).
TAVAREC Randomised phase II trial assessing the significance of Bevacizumab in recurrent grade II and grade III gliomas.
CHECKMATE 143 A Randomized Phase IIB Open Label Study of Nivolumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma
GSK FAK Phase I study of a Focal Adhesion Kinase Inhibitor in Subjects with Solid Tumors (NCT01138033)
DCVax Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
CHECKMATE 498 (NCT02617589) Study of Nivolumab Versus Temozolomide, Given with Radiation Therapy, for Newly-diagnosed Patients with Glioblastoma
CHECKMATE 548 (NCT02667587) Study of Temozolomide Plus Radiation Therapy with Nivolumab or Placebo, for Newly Diagnosed Patients with Glioblastoma
BBC News: Man's brain tumour shrinks by half in therapy trial
A man's brain tumour has shrunk by half in weeks thanks to a new radioactive therapy. Paul Read, 62, from Luton, was the first patient to take part in a trial aimed at treating glioblastoma.
Brain cancer trial recruits largest ever number of patients
A clinical trial for patients with brain cancer, designed by a UCL scientist, has recruited more UK participants than ever before for a study of its kind.
